The human intestinal cell line Caco-2 was used as a model system to study the effects of epidermal growth factor (EGF) on peptide transport. EGF decreased apical-to-basolateral fluxes of [14C]glycylsarcosine ([14C]Gly-Sar) up to 50.2 ± 3.6% ( n = 6) of control values. Kinetic analysis of the fluxes showed that maximal flux ( Vmax) of transepithelial transport decreased from 3.00 ± 0.17 nmol · cm−2· min−1in control cells to 0.50 ± 0.07 nmol · cm−2· min−1in cells treated with 5 ng/ml EGF ( n = 6, P < 0.01). The apparent Michaelis-Menten constant ( Km) was 2.71 ± 0.31 mM ( n= 6) in control cells and 1.89 ± 0.28 mM ( n = 6, not significantly different from control) in EGF-treated cells. Similarly, apical uptake of [14C]Gly-Sar decreased in cells treated with EGF, with an ED50value of 0.36 ± 0.06 ng/ml ( n = 6) EGF and a maximal inhibition of 80 ± 0.02% ( n = 6). Vmaxdecreased from 2.61 ± 0.4 to 1.06 ± 0.1 nmol · cm−2· min−1( n = 3, P < 0.05), whereas Kmremained constant. Basolateral Gly-Sar uptake showed no changes in Vmaxor Kmafter EGF treatment ( n = 3). RT-PCR showed a decrease in hPepT1 mRNA (using glucose-6-phosphate dehydrogenase mRNA as control) in cells treated with EGF. Western blotting indicated a decrease in hPepT1 protein in cell lysates. We conclude that EGF treatment decreases Gly-Sar transport in Caco-2 cells by decreasing the number of peptide transporter molecules in the apical membrane.